We examined standard-of-care treatments, such as temozolomide for glioblastoma multiforme (GBM) and gemcitabine for bladder cancer, as well as more recently developed Chk1 inhibitors (Chk1i). This evidence concerns the gene CHEK1 and glioblastoma.